Progressing Gastrointestinal Stromal Tumor
Watch
Treatment Options in Gastrointestinal Stromal Tumors
Molecular Testing in Gastrointestinal Stromal Tumors
Presentation of a Gastrointestinal Stromal Tumor Case
Case of A 68-Year-Old Man With Gastrointestinal Stromal Tumor
Neeta Somaiah, MD, reviews the case of a 68-year-old man with gastrointestinal stromal tumor.
Genomic Testing Recommended for Patients With Thyroid Cancer
Marcia Brose, MD, PhD, discusses the importance of genomic testing in patients with thyroid cancer.
Dysphagia-Optimized IMRT Shows Significance in Head and Neck Cancer
Christopher Nutting, MD, discusses the results of a randomized phase 3 trial using dysphagia-optimized intensity modulated radiotherapy versus standard IMRT in patients with head and neck cancer.
R/R HER2+ mBC Management During COVID-19 Pandemic
HER2CLIMB FDA Approval
Currently Accepted Regimens: NCCN Guidelines
HER2-Positive mBC Emerging Treatment Landscape
The Evolving Role of Tucatinib in HER2-Positive Metastatic Breast Cancer
A key opinion leader discusses how the role tucatinib is evolving in the management of HER2-positive metastatic breast cancer.
Evaluating CPI-0610 as Treatment of Patients With Myelofibrosis
Srdan Verstovsek, MD, PhD, discusses the potential role of CPI-0610 as treatment of patients with myelofibrosis.
Investigators Observe Differences in Toxicity for Sarcoma Due to Dosing
Gary K. Schwartz, MD, discusses adverse events seen in patients with metastatic sarcoma participating in the Alliance A091401 trial.
Future Directions in High-Risk Ovarian Cancer
Rucaparib Maintenance Therapy for High-Risk Ovarian Cancer
Maintenance Therapy for Advanced Ovarian Cancer
Rucaparib for Relapsed Ovarian Cancer: Safety Profile
Rucaparib: Clinical Activity in Relapsed Ovarian Cancer
Rucaparib Explored for High-Risk Ovarian Cancer
Advanced Ovarian Cancer Treatment Strategies
Outlook for Patients With High-Risk Ovarian Cancer
Case Overview: High-Risk Ovarian Cancer
A 71-Year-Old Woman With High-Risk Ovarian Cancer
Ramez N. Eskander, MD, explains the rationale for treating a 71-year-old woman with ovarian cancer with the PARP inhibitor rucaparib upon relapse.
CAR T-Cell Therapy Evolves in Leukemia Treatment Landscape
Jae H. Park, MD, discusses the role of chimeric antigen receptor T-cell therapy in leukemias and how he sees this treatment evolving in the coming years.
Discussing Recent Advances and Clinical Trials in Bladder Cancer
Matthew Galsky, MD, discusses the most recent data in patients with bladder cancer.
Multikinase Inhibitor Overall Survival Advantage
Radioiodine-Refractory DTC: NCCN Guidelines
What is Radioiodine-Refractory DTC?
SELECT Trial: Toxicity, Duration of Response, and Dose Reduction
